Logo image
RACIAL DISPARITIES IN CANCER GUIDELINE CONCORDANT TREATMENT USING SEER DATA FOR NON-SMALL CELL LUNG CANCER PATIENTS
Journal article   Open access   Peer reviewed

RACIAL DISPARITIES IN CANCER GUIDELINE CONCORDANT TREATMENT USING SEER DATA FOR NON-SMALL CELL LUNG CANCER PATIENTS

Eric Ababio Anyimadu, Jacklyn Engelbart, Jason Semprini, Amanda Kahl, Cameron Trentz, John M. Buatti, Thomas Casavant, Mary Charlton and Guadalupe Canahuate
JTO clinical and research reports, Vol.6(1), 100747
01/2025
DOI: 10.1016/j.jtocrr.2024.100747
PMCID: PMC11699381
PMID: 39758596
url
https://doi.org/10.1016/j.jtocrr.2024.100747View
Published (Version of record) Open Access

Abstract

Despite efforts to achieve healthcare equality, racial/ethnic disparities persist in lung cancer survival in the United States, with Non-Hispanic Black patients experiencing higher mortality compared to Non-Hispanic Whites. Prior research often focused on single treatments, overlooking the broad range of options available. We aimed to highlight disparities in survival and receipt of comprehensive lung cancer treatment by developing a Guideline Concordant Initial Treatment (GCIT) indicator based on disease stage and recommended treatment. Using SEER data on 377,370 Non-Small Cell Lung Cancer patients, we derived a GCIT indicator based on National Comprehensive Cancer Network guidelines. Observed probabilities and logistic regression models adjusted for age, disease stage, and race were used to assess racial disparities in treatment and survival, with the Kaplan-Meier method evaluating survival rates. Racial/ethnic groups analyzed included Non-Hispanic White, Non-Hispanic Black, Asian/Pacific Islander, Hispanic, and American Indian/Alaska Native. Non-Hispanic Black patients had lower odds of receiving GCIT (OR 0.80; 95% CI 0.78–0.82) and surviving two years post-diagnosis (OR 0.80; 95% CI 0.78–0.82). Non-Hispanic Asians had the highest odds of receiving GCIT (OR 1.02; 95% CI 0.99–1.05). Patients receiving GCIT showed improved survival, with early-stage patients experiencing median survival of 67-102 months, compared to 11-17 months for those without GCIT. Receiving GCIT significantly improves survival across all races, though disparities in receipt are observed. Interventions are needed to ensure equitable access to guideline-concordant care and reduce survival disparities for patients.
Disparities Guideline Concordant Initial Treatment Non-Small Cell Lung Cancer

Details

Metrics

2 readers on Mendeley
Logo image